Bayer ( BAYRY.PK ) and Onyx Pharmaceuticals ( ONXX ) announce a Phase 3 trial of Nexavar tablets in patients with certain lung cancers did not meet its primary endpoint of improving overall survival. Post your comment!
… the conference, including Aosaikang, AstraZeneca, Bayer HealthCare , BeiGene, Boehringer Ingelheim, Eli Lilly, Fosun Pharma, Furen Pharma, Hanmi Pharmaceutical, Hengrui Pharmaceuticals , Hua Medicine, Janssen/J&J, Life Technologies …
… established global brands such as Siemens, Bayer , Daimler, and SAP. Given the export ..... such as Siemens, BASF, Daimler, and Bayer . That said, this fund has a cyclical ..... industries such as financial services, pharmaceuticals , and automobile manufacturing. EWG …
Just looked at the intersection for two portfolios that have American Funds and others with holdings in Bayer AG . In both cases, each portfolio repeated the entry line 7 times with all having the same funds and values. Not a problem, just wanted to report this bug. John
Onyx Pharmaceuticals ' ONXX first-quarter results came in generally in line with our expectations ..... In first quarter, revenue from Onyx's collaboration agreement with Bayer BAYRY on Nexavar sales was $72.0 million, representing a 7% increase …
… not yet become reflected in Maxygen's stock price. Bayer Healthcare ( BAYZF.PK ) recently disclosed in a recent investor ..... trading only modestly above cash, the realization of the Bayer payment will likely serve as a key catalyst that will …
… of products can help insulate Bayer from economic gyrations. Bayer 's entrenchment in biologics ..... manufacture, and market. Bayer has been establishing a strong ..... invested capital perspective. Bayer AG is a German health-care and …
(The following statement was released by the rating agency)
… Overview -- Germany-based pharmaceuticals , polymers, and agrochemicals conglomerate Bayer AG continues to deliver strong ..... revising our outlook on Bayer to positive from stable ..... corporate credit ratings on Bayer . -- The positive outlook …
FRANKFURT, April 25 (Reuters) - German drugs and plastics maker Bayer AG is close to making a multi-billion euro acquisition to bolster its healthcare division, three people close to the planned transaction said.